J Low Genit Tract Dis. 2011;15:158–60.PubMedCrossRef selleck inhibitor 20. Bryan CS. Fatal pyoderma gangrenosum with pathergy after coronary artery bypass grafting. Tex Heart Inst J. 2012;39:894–7.PubMed 21. Ryu J, Naik H, Yang FC, Winterfield L. Pyoderma gangrenosum presenting with leukemoid reaction: a report of 2 cases. Arch Dermatol. 2010;146:568–9.PubMedCrossRef 22. Smith GL, Bunker CB, Dineeen MD. Fournier’s gangrene. Br J Urol. 1998;81:347–55.PubMedCrossRef

23. Thwaini A, Khan A, Malik A, et al. Fournier’s gangrene and its emergency management. Postgrad Med J. 2006;82:516–9.PubMedCrossRef 24. Elliott D, Kufera JA, Myers RA. The microbiology of necrotizing soft tissue infections. Am J Surg. 2000;179:361–6.PubMedCrossRef 25. Callen JP, Jackson JM. Pyodermagangrenosum: an update. Rheum Dis Clin N Am. 2007;33:787–802.CrossRef”
“Introduction Psoriasis is a chronic inflammatory systemic disease predominantly affecting the skin and joints. The prevalence ranges between 0.9% (United States) and 8.5% (Norway) [1]. Skin lesions are the major manifestation of the disease. PCI-32765 cell line They are described as scaling and erythematous

plaques that may be pruritic or painful and cause significant quality of life issues [2]. The new era of biologic therapies offers outstanding options for the treatment of chronic plaque psoriasis, and these agents have proved to be remarkable in improving patient quality of life compared with classical antipsoriatic

treatments. However, despite the high efficacy, there have always been CH5183284 mouse concerns regarding the safety of these agents as all anti-tumor necrosis factor alpha (anti-TNF-alpha) agents have been associated with activation of latent tuberculosis infection (LTBI) in a relatively short period of time [3]. According to World Health Organization (WHO), the global incidence of tuberculosis (TB) is estimated to 125 cases per 100,000 population [4]. The progression or reactivation of TB should be expected and such concerns 5-Fluoracil cell line have led to intensive screening and monitoring of patients receiving anti-TNF therapies [5]. Current screening includes medical history, chest X-ray, and tests for evaluating the immunologic response to the presence of Mycobacterium tuberculosis, such as the tuberculin skin test (TST) and interferon gamma release assays (IGRAs) [6]. Current guidelines recommend TST as the main screening tool for LTBI in patients with psoriasis before initiation of anti-TNF therapy, but there is a lack of consensus on the interpretation of TST in this group of patients [7–9]. The European S3 guidelines recommend the use of either TST or IGRAs or both for LTBI detection [10]. However, as TST may produce false-positive results, the newest recommendations suggest the use of IGRAs [11]. Despite the screening programs for LTBI identification prior to anti-TNF therapy, the risk of developing active TB is still present.